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The value of biomarkers that report on the effects 
of drugs at the target site –  largely non-
invasive/imaging  biomarkers  -  is increasingly being 
recognised. Such biomarkers can inform whether the 
drug modulates the target in the desired manner, as 
well as the magnitude and duration of target 
modulation and recovery dynamics. Correlative 
investigations with dynamic  contrast-enhanced 
magnetic resonance imaging (DCE-MRI) and 
[
18F]fluorodeoxyglucose positron emission tomography 
(PET) are routinely employed during first-in-human 
studies of antiangiogenic/antivascular therapies. There 
is a broad range of non-invasive imaging/spectroscopic 
methodologies capable of reporting drug 
pharmacodynamics at the tumour site [1]. Whereas 
some imaging/spectroscopic approaches are specific to 
the biological target protein, others report changes in 
signalling pathway activity or indeed phenotype. 
  The ‘phosphatidylcholine transformation and 
progression signature’ (PTPS) is one such phenotype 
that can be exploited to assess target drug effect. This 
signature, which is fairly generic in tumours, has been 
described extensively for breast cancer [2-7], and to a 
lesser extent brain [8], prostate [9], ovarian [10] and 
other cancers. In these cancers, PTPS is characterized 
by high phosphocholine (PC) levels relative to 
glycerophosphocholine (GPC), resulting primarily 
from increased choline kinase activity [4]. PC levels 
increase in the order senescent mortal cells < cells 
exhibiting immortalized anchorage-dependent growth 
< cells exhibiting immortalized anchorage-independent 
growth < tumorigenic low metastaticity cells < 
tumorigenic high metastaticity cells; this is analogous 
to the transformation and progression of normal cells to 
benign hyperplasia followed by atypical hyperplasia, 
which progresses to carcinoma in situ and finally to 
infiltrating carcinoma with or without metastasis to 
distant sites [11]. Growth factor receptor→Ras→Erk 
signal transduction can increase PC levels in cells [2, 
12, 13]. Two non-invasive approaches can be used to 
assess PTPS, namely magnetic resonance spectroscopy 
(MRS) and PET. PET imaging approaches measure the 
biosynthesis of PC [11, 12, 14], while MRS-based 
approaches measure PC derived from both biosynthesis 
and degradation of phosphatidylcholine; it could be 
argued, however, that majority of PC results from 
biosynthesis during cell growth. Hence both nuclear 
and MRS approaches have the ability to detect the 
effects of drugs that alter tumor PTPS through 
inhibition of cell signalling mechanisms or 
proliferation, the endpoint being a reduction in PC 
(Figure). Other characteristics of the PTPS are related 
to increases in GPC levels, and indeed, an early event 
of transformation is a switch from high GPC/PC ratio 
to low GPC/PC. High GPC, which may result from the 
actions of phospholipase A1 and A2 and 
lysophospholipase, could be considered a reduced 
malignant phenotype. This latter signature may also 
result from increased cell death or induction of 
differentiation, the endpoint being increases in GPC 
and related free fatty acids (Figure). 
The work presented by Beloueche-Babari et al in 
this issue accords with the prevailing view on 
exploitation of PTPS for assessing drug effects. They 
examined the metabolic response of melanoma cells to 
inhibition of cell growth by a heat shock protein 90 
(Hsp90) inhibitor. Using MRS, they provide proof that, 
concomitant with growth inhibition and induction of 
differentiation, the hsp90 inhibitor, 17-AAG, alters the 
PTPS of melanoma cells in a predictable manner, 
leading to no changes in PC and increases in GPC, free 
fatty acyl chains and cytoplasmic lipid droplets. These 
biochemical changes are consistent with normalization 
of PTPS. It is often unclear if cellular effects are 
                       
Phosphatidylcholine Metabolic Transformation and Progression 
Signature as a Pharmacodynamic Biomarker 
 
Eric O. Aboagye 
 
Comprehensive Cancer Imaging Centre, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, 
Hammersmith Hospital Campus, London W12 0NN, UK 
 
Correspondence to:  Eric Aboagye, email: eric.aboagye@imperial.ac.uk 
 
Key words: Hsp90, PTPS, magnetic resonance spectroscopy, melanoma, pharmacodynamic biomarker  
Received: June 24, 2010,    Accepted: July13, 2010,    Published: July 14, 2010  
  
www.impactjournals.com/oncotarget    164      Oncotarget 2010; 1: 163-166 
 
chemotype-specific (related to the specific structure of 
drug) or target-specific. In this context they examined a 
structurally dissimilar Hsp90 inhibitor and showed that 
the effect was independent of specific Hsp90 inhibitor. 
Imaging and spectroscopic methods that exploit the 
PTPS may have clinical value as target-tissue 
pharmacodynamic biomarkers in melanoma and other 
solid tumors. Activating mutations in BRAF occur in 
~7% of all human cancers including melanoma, 
papillary thyroid and colon cancer; the V600E 
mutation is the most common mutation occurring in 
approximately 70% of melanoma patients [15]. 
Activated mutant BRAF binds to an Hsp90-cdc37 
complex, which is required for its stability and 
function. Hsp90 inhibitors disrupt protein stability and, 
hence, cognate biochemical processes such as MAP 
kinase signaling. Due to the ability of Hsp90 inhibitors 
to target several oncogenic proteins, melanomas with 
activating BRAF mutations, as well as those with WT 
BRAF activated by NRAS alike are sensitive to 
inhibitors like 17AAG [16, 17]. Hence, this is a patient 
population in which drug pharmacology can be 
objectively assessed and non-responders can be readily 
identified for alternative therapy. The work by 
Beloueche-Babari et al offers several insights into the 
potential role of exploiting tumor PTPS normalization 
as a non-invasive biomarker of anticancer drug effect 
in general, and specifically, potential use of these 
methods in melanoma patients for assessing response 
to Hsp90 inhibitors, as well as other agents like MEK 
inhibitors that target associated pathways [18, 19]. The 
study also raises a number of questions around the in 
vivo  application of PTPS normalization as a non-
invasive biomarker that require further investigation. 
Standard 31P-MRS methods do not sufficiently resolve 
individual choline metabolite resonances. Instead 
composite peaks: phosphomonoesters (comprising PC 
and phosphoethanolamine) and phosphodiesters 
(comprising GPC and glycerophosphoethanolamine), 
are  detected in humans MRS measurements [20]. 
Further studies are, therefore, warranted to determine 
whether the composite phosphomonoester and 
phosphodiester resonances are altered with Hsp90 
inhibition in melanoma, since these are more clinically 
assessable measures; the methods have been 
standardized and reproducibility has been determined 
in the multi-institutional setting [20]. Alternatively, 
1H-decoupled 31P-MRS has shown promise for 
resolving the metabolite resonances depending on 
target tissue homogeneity and could be explored for 
measurement of PTPS normalization [20]. 1H-MRS 
can be used to assess the tissue levels of CH2-free fatty 
acyl  chains that give rise to the MR-visible mobile 
lipids [21, 22]. Beloueche-Babari et al provide a body 
of evidence, including inhibition of calcium-
independent phospholipase A2, to support assessment 
of these lipid resonances as biomarkers of drug effect. 
It will be interesting to demonstrate how the free fatty 
acyl chain resonances change with Hsp90 inhibition in 
vivo in animal models of melanoma and in patients. 
Beloueche-Babari  et al  demonstrate that the time-
dependent evolution of the drug-related changes on 
growth mirror changes in the biomarker signature. This 
is important in assigning pharmacological relevance to 
the biomarker signature. Investigation of the dose-
dependence of these PTPS readouts will further support 
the pharmacological relevance of the biomarker. In this 
context it will be useful to know whether the 
spectroscopic readout evolves as all-or-nothing 
phenomena or are indeed dose-related; the latter will be 
Fig:  Normalization of the ‘phosphatidylcholine 
transformation and progression signature’ (PTPS) as a 
pharmacodynamic biomarker of target tissue drug 
inhibition. As normal cells transform and progress 
towards a more malignant phenotype, levels of 
phosphatidylcholine biosynthetic product, 
phosphocholine (PC) increases . Proliferation and 
mitogenic signaling events also increase PC. In contrast, 
cell death and differentiation, promote degradation of 
phosphatidylcholine leading increases in the metabolites, 
glycerophosphocholine (GPC) and associated free fatty 
acids (detectable as free fatty acyl chains). This 
phenotype is opposite to an early event in transformation 
that involves conversion of high GPC/PC ratio to low 
GPC/PC ratio. Hence drugs that inhibit proliferation, 
inhibit cell signaling, induce differentiation, or induce 
cell death could be hypothesized to alter PTPS. In this 
edition of the Journal, the role of PTPS normalization as 
a biomarker of Hsp90 inhibition has been investigated by 
Beloueche-Babari and co-workers.    
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amenable to investigation of drug effects in early 
clinical trials of future inhibitors.  
In summary, normalization of tumor PTPS appears 
to be a realistic biomarker for non-invasive monitoring 
of the pharmacological action of Hsp90 inhibitors. The 
potential value of this biomarker should be tested  in 
vivo. 
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